A big pharma name in India is tying up with an AI diagnostics startup. Sanofi’s local arm signed a letter of intent with Tricog Health that could lead to three years of support.
Under the pact, Sanofi would offer mentoring, help with market access, and possibly invest. Tricog sells virtual cardiac diagnostics, blending algorithms with clinical review to interpret ECG data.
The signing happened in front of Sebastien Coisne, who handles finance for Sanofi’s general medicines business internationally, and senior IIT Kanpur figures. The two sides met at Bharat Innovates 2026, an Indian government showcase that flew 120 deep-tech startups to France.
Timing also matters. India and France declared 2026 their year of innovation, and this deal is a private-sector echo of that push.
Sanofi India’s managing director, Deepak Arora, framed the move as a bet on collaboration between science, business, and public institutions, with AI speeding up India’s health innovation.
Tricog’s chief growth officer, Prateek Golecha, said Sanofi’s reach and know-how could carry the startup’s AI heart diagnostics beyond India.
The deal is another sign that drugmakers want digital partners who find and follow cardiovascular patients, not just treat them after diagnosis.
